Cargando…
[(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
BACKGROUND: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [(18)F]Fluoro-Methyl Choline ([(18)F]FMCH) PET/CT in the selec...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885020/ https://www.ncbi.nlm.nih.gov/pubmed/31620808 http://dx.doi.org/10.1007/s00259-019-04482-6 |
_version_ | 1783474668729008128 |
---|---|
author | Pasqualetti, Francesco Panichi, Marco Sollini, Martina Sainato, Aldo Galli, Luca Morganti, Riccardo Chiacchio, Serena Marciano, Andrea Zanca, Roberta Mannelli, Lorenzo Coraggio, Gabriele Sbrana, Andrea Cocuzza, Paola Montrone, Sabrina Baldaccini, Davide Gonnelli, Alessandra Molinari, Alessandro Cantarella, Martina Mazzotti, Valentina Ricci, Sergio Paiar, Fabiola Erba, Paola Anna |
author_facet | Pasqualetti, Francesco Panichi, Marco Sollini, Martina Sainato, Aldo Galli, Luca Morganti, Riccardo Chiacchio, Serena Marciano, Andrea Zanca, Roberta Mannelli, Lorenzo Coraggio, Gabriele Sbrana, Andrea Cocuzza, Paola Montrone, Sabrina Baldaccini, Davide Gonnelli, Alessandra Molinari, Alessandro Cantarella, Martina Mazzotti, Valentina Ricci, Sergio Paiar, Fabiola Erba, Paola Anna |
author_sort | Pasqualetti, Francesco |
collection | PubMed |
description | BACKGROUND: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [(18)F]Fluoro-Methyl Choline ([(18)F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). METHODS: Patients with biochemical recurrence limited up to three lesions revealed by [(18)F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [(18)F]FMCH PET/CT was considered as the primary endpoint. RESULTS: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). CONCLUSIONS: Based on our findings, [(18)F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months. |
format | Online Article Text |
id | pubmed-6885020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-68850202019-12-12 [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer Pasqualetti, Francesco Panichi, Marco Sollini, Martina Sainato, Aldo Galli, Luca Morganti, Riccardo Chiacchio, Serena Marciano, Andrea Zanca, Roberta Mannelli, Lorenzo Coraggio, Gabriele Sbrana, Andrea Cocuzza, Paola Montrone, Sabrina Baldaccini, Davide Gonnelli, Alessandra Molinari, Alessandro Cantarella, Martina Mazzotti, Valentina Ricci, Sergio Paiar, Fabiola Erba, Paola Anna Eur J Nucl Med Mol Imaging Original Article BACKGROUND: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [(18)F]Fluoro-Methyl Choline ([(18)F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). METHODS: Patients with biochemical recurrence limited up to three lesions revealed by [(18)F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [(18)F]FMCH PET/CT was considered as the primary endpoint. RESULTS: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). CONCLUSIONS: Based on our findings, [(18)F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months. Springer Berlin Heidelberg 2019-10-16 2020 /pmc/articles/PMC6885020/ /pubmed/31620808 http://dx.doi.org/10.1007/s00259-019-04482-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Pasqualetti, Francesco Panichi, Marco Sollini, Martina Sainato, Aldo Galli, Luca Morganti, Riccardo Chiacchio, Serena Marciano, Andrea Zanca, Roberta Mannelli, Lorenzo Coraggio, Gabriele Sbrana, Andrea Cocuzza, Paola Montrone, Sabrina Baldaccini, Davide Gonnelli, Alessandra Molinari, Alessandro Cantarella, Martina Mazzotti, Valentina Ricci, Sergio Paiar, Fabiola Erba, Paola Anna [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title | [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title_full | [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title_fullStr | [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title_full_unstemmed | [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title_short | [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
title_sort | [(18)f]fluorocholine pet/ct-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885020/ https://www.ncbi.nlm.nih.gov/pubmed/31620808 http://dx.doi.org/10.1007/s00259-019-04482-6 |
work_keys_str_mv | AT pasqualettifrancesco 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT panichimarco 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT sollinimartina 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT sainatoaldo 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT galliluca 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT morgantiriccardo 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT chiacchioserena 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT marcianoandrea 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT zancaroberta 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT mannellilorenzo 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT coraggiogabriele 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT sbranaandrea 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT cocuzzapaola 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT montronesabrina 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT baldaccinidavide 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT gonnellialessandra 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT molinarialessandro 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT cantarellamartina 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT mazzottivalentina 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT riccisergio 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT paiarfabiola 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer AT erbapaolaanna 18ffluorocholinepetctguidedstereotacticbodyradiotherapyinpatientswithrecurrentoligometastaticprostatecancer |